Highest-materiality recent filing
MediciNova FY2025 net loss per share $0.24, operating loss $13.3M, cash down to $30.8M
Net loss attributable to shareholders $12.0M ($0.24 per share) vs $11.0M ($0.23) in FY2024.
MediciNova enters equity distribution agreement for up to $50M at-the-market offering
Agreement with Lucid Capital Markets as sales agent for at-the-market sales of common stock.
MediciNova CFO Douglas Paulin resigns; Jason J. Kruger appointed as new CFO
Effective June 16, 2022, Douglas Paulin resigned as CFO; Jason J. Kruger appointed as CFO and Principal Financial Officer.
MediciNova may receive portion of Genzyme's damages from Novartis Zolgensma patent suit
Genzyme filed First Amended Complaint on Feb 23, 2022 in Delaware court adding U.S. Patent No. 9,051,542 against Novartis over Zolgensma.
Edward Stepanow resigned as CFO effective July 31, 2021; no reason given.
On March 26, 2024, Geoffrey O’Brien informed MediciNova, Inc. (the “Company”) of his decision to retire from full-time employment and resign from his employment with the Company, effective as of April 2, 2024.
On August 4, 2023, the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) appointed Nicole Lemerond as a member of the Board, effective immediately, filling an existing vacancy on the Board.
On April 20, 2023, Jeff Himawan, Ph.D., a member of the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) notified the Board that he will not stand for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”) due solely to a personal decision related to health reasons.
Effective June 16, 2022, Douglas Paulin resigned as Chief Financial Officer of MediciNova, Inc.
In addition, effective August 1, 2021, the Board appointed Douglas Paulin, CPA, of the accounting services firm Signature Analytics San Diego LLC (“Signature Analytics”) to serve as Chief Financial Officer and Principal Financial Officer of the Company.
Effective July 31, 2021, Edward Stepanow resigned as Chief Financial Officer of MediciNova, Inc. (the “Company”).
Max materiality 0.65 · Median 0.35 · Most common event other_material